RB1 and non-small cell lung carcinoma: A study that analyzed seven patients whose disease had transformed into SCLC found that the transformation rate for those with advanced NSCLC and EGFR mutations (3%) was significantly lower—by a factor of six—compared to those with EGFR/RB1/TP53 mutations (18%).